Valuation: Axsome Therapeutics, Inc.

Market Cap 12.48B 10.93B 10.07B 9.35B 17.75B 1,191B 17.99B 121B 46.91B 585B 46.88B 45.85B 2,027B P/E 2026 *
-123x
P/E 2027 * 42.5x
Enterprise Value 12.37B 10.84B 9.98B 9.26B 17.59B 1,180B 17.83B 119B 46.5B 579B 46.47B 45.45B 2,009B EV / Sales 2026 *
12.6x
EV / Sales 2027 * 7.57x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.70%
1 week+0.61%
Current month-0.89%
1 month+4.42%
3 months+42.92%
6 months+41.14%
Current year+32.83%
1 week 237.64
Extreme 237.64
251.25
1 month 233.29
Extreme 233.29
260.19
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 11/01/2012
Director of Finance/CFO 51 15/05/2018
Chief Operating Officer 42 31/03/2014
Director TitleAgeSince
Chairman 57 11/01/2012
Director/Board Member 64 30/11/2014
Director/Board Member 58 30/11/2014
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Executive Officer

148,998 0.2895%
06-10Sell

Director

-286 0.0006%
06-09Sell

Director

-300 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%+0.61%+130.08%+228.24% 12.48B
-0.68%+2.85%+18.72%-7.81% 66.11B
-0.24%-3.09%+49.44%+224.10% 55.3B
-1.13%+40.50%+40.50%+40.50% 42.44B
-0.21%+8.04%-50.01%-53.55% 41.28B
-3.54%-3.77%+56.89%-26.85% 30.78B
+2.56%+17.36%+168.28%-30.85% 32.46B
-1.06%+0.84%+68.91%+83.93% 23.1B
-3.65%+9.55%+5.63%+188.26% 20.06B
-0.48%+3.59%+67.34%+135.30% 17.19B
Average -0.91%+4.78%+55.58%+78.13% 34.12B
Weighted average by Cap. -0.74%+3.92%+44.92%+59.93%

Financials

2026 *2027 *
Net sales 985M 863M 795M 738M 1.4B 93.98B 1.42B 9.51B 3.7B 46.13B 3.7B 3.62B 160B 1.6B 1.4B 1.29B 1.2B 2.27B 152B 2.3B 15.43B 6B 74.8B 6B 5.87B 259B
Net income -102M -89.62M -82.55M -76.62M -146M -9.76B -147M -988M -385M -4.79B -384M -376M -16.61B 315M 276M 254M 236M 448M 30.07B 454M 3.04B 1.18B 14.76B 1.18B 1.16B 51.17B
Net Debt -111M -96.95M -89.29M -82.89M -157M -10.56B -160M -1.07B -416M -5.18B -416M -407M -17.97B -394M -345M -318M -295M -560M -37.56B -568M -3.8B -1.48B -18.44B -1.48B -1.45B -63.93B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
06/07/26 US$242.60 -0.70% 842,382
02/07/26 US$244.31 +1.52% 854,306
01/07/26 US$240.66 -1.68% 977,820
30/06/26 US$244.77 +1.51% 1,195,972
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
242.60USD
Average target price
276.47USD
Spread / Average Target
+13.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock